AxCell Biosciences Previews ProChart(TM), Its Novel Proteomics Database Product

Six City Seminar Series for Leaders in the Pharmaceutical and Biotechnology

Industries is Successfully Completed



Launch of ProChart(TM) Database Expected in April



Apr 04, 2001, 01:00 ET from Cytogen Corporation

    PRINCETON, N.J., April 4 /PRNewswire/ -- AxCell Biosciences Corporation, a
 subsidiary of Cytogen Corporation (Nasdaq: CYTO), today announced that, in
 conjunction with InforMax, it successfully completed a seminar series on high-
 throughput research featuring the Company's ProChart(TM) database product.
 ProChart, formerly known as the Inter-Functional Proteomic Database(TM), is a
 proprietary protein pathway database which measures protein domain-ligand
 interactions in a high-throughput manner.  ProChart will be marketed by
 InforMax, Inc. within its GenoMax(TM) enterprise bioinformatics platform.
 During March, the Company displayed ProChart in six cities across the United
 States using InforMax's Protein-Protein Interaction module, a new addition to
 the GenoMax(TM) enterprise software package.  This six-city seminar series,
 which highlighted the technology behind ProChart and detailed the use of the
 database in pharmaceutical research, was designed by InforMax to showcase
 their, and partner, products and services and provide an educational forum for
 pharmaceutical scientists and researchers on commercial advances in
 bioinformatics, genomics and proteomics.
     "With such data, researchers may better pinpoint pathway changes
 associated with diseases and more accurately select points of intervention for
 treatment," said John D. Rodwell, Ph.D, President and Chief Technology Officer
 of AxCell.  "We believe that these seminars have helped prepare the market for
 launch of ProChart this month."
     In addition, AxCell has finalized plans for expansion at its Newtown, PA
 facilities.  Construction will begin shortly which, when complete, will add
 approximately 5500 sq. ft. of workspace, virtually all of which will be used
 for laboratory space for increased molecular biology, chemistry and screening
 activities designed to accelerate the acquisition of protein interaction data
 for use in its ProChart database product and for more effective mining of its
 data.
     As part of its efforts to acquaint the pharmaceutical and biotechnology
 markets with its ProChart product, AxCell will be presenting at a number of
 future conferences.  The Company is currently scheduled to speak at the 5th
 Annual Congress on Drug Discovery in Stuttgart, Germany in April, the
 Proteomics 2001 Conference in Philadelphia in May, the HTT Expo in
 Philadelphia and the Proteomics Conference in San Francisco which both take
 place in June.
 
     Cytogen Hires Financial Advisor
     Cytogen Corporation is currently engaged in two highly competitive lines
 of business; oncology and proteomics.  Cytogen recognizes the need to
 strengthen each of its businesses in order to enhance shareholder value.
 Given the challenges of increasing shareholder value and raising capital in
 today's marketplace, the Board of directors has engaged UBS Warburg LLC as its
 financial advisor in order to assist the Company in pursuing various strategic
 alternatives, including but not limited to marketing arrangements, research
 and development collaborations, international collaborations, joint ventures
 and financing opportunities.
 
     About AxCell Biosciences
     AxCell Biosciences Corporation is conducting research and development in
 functional proteomics, the identification of protein interactions and
 signaling pathways within cells and their relationship to disease processes.
 Proteomics research efforts can be categorized as structural and functional.
 Structural proteomics, or protein expression, measures the number and types of
 proteins present in normal and diseased cells.  This approach is useful in
 defining the structure of proteins in a cell.  Some of these proteins may be
 targets for drug discovery.  However, the role of the protein in the disease
 is still not defined.  AxCell's proteomics business is focused upon functional
 proteomics, the study of proteins' biological activities.  An important
 function of proteins is the transmission of signals using intricate pathways
 populated by proteins which interact with one another.  Elucidating the role
 proteins play in these signaling pathways allows a better understanding of
 their function in cellular behavior and permits identification of potential
 drug targets.  Protein-protein interactions form the core of the Company's
 ProChart(TM) Database.  AxCell's plans to offer ProChart(TM) to the
 pharmaceutical industry as a tool to accelerate the drug discovery process.
 For additional information on AxCell Biosciences, visit www.axcellbio.com.
 
     About Cytogen Corporation
     Cytogen Corporation is a biopharmaceutical company based in Princeton, NJ.
 The Company's two principal lines of business, proteomics and oncology, are
 built upon its expertise in antibodies and molecular recognition and are
 directed principally to development of novel products for the diagnosis,
 imaging, staging and treatment of prostate cancer and a proteomics-driven drug
 discovery platform.  For additional information, visit www.cytogen.com.
 
     This press release contains certain "forward-looking" statements within
 the meaning of the Private Securities Litigation Reform Act of 1995.
 Information in this press release, which is not historical, is forward-looking
 and involves a number of risks and uncertainties including those discussed in
 the Company's 2000 Form 10-K and from time-to-time the Company's other filings
 with the Securities and Exchange Commission.  Investors are cautioned not to
 put any undue reliance on any forward-looking statement.  The Company's actual
 results may differ materially from those anticipated in these forward-looking
 statements.  Factors that may cause such differences include, but are not
 limited to, uncertainties associated with the Company's ability to sustain its
 intellectual property positions on its proteomics technology, and the
 successful development and market acceptance of the technology.  In
 particular, the Company cannot assure you that the protein interaction program
 will result in the commercialization of a successful product or whether any
 strategic alternative or financing will be available at all on terms that are
 in the best interests of the Company and its shareholders.  The Company
 specifically disclaims any intention or duty to update any forward-looking
 statements, and these statements represent the Company's outlook at this time.
 
 

SOURCE Cytogen Corporation
    PRINCETON, N.J., April 4 /PRNewswire/ -- AxCell Biosciences Corporation, a
 subsidiary of Cytogen Corporation (Nasdaq: CYTO), today announced that, in
 conjunction with InforMax, it successfully completed a seminar series on high-
 throughput research featuring the Company's ProChart(TM) database product.
 ProChart, formerly known as the Inter-Functional Proteomic Database(TM), is a
 proprietary protein pathway database which measures protein domain-ligand
 interactions in a high-throughput manner.  ProChart will be marketed by
 InforMax, Inc. within its GenoMax(TM) enterprise bioinformatics platform.
 During March, the Company displayed ProChart in six cities across the United
 States using InforMax's Protein-Protein Interaction module, a new addition to
 the GenoMax(TM) enterprise software package.  This six-city seminar series,
 which highlighted the technology behind ProChart and detailed the use of the
 database in pharmaceutical research, was designed by InforMax to showcase
 their, and partner, products and services and provide an educational forum for
 pharmaceutical scientists and researchers on commercial advances in
 bioinformatics, genomics and proteomics.
     "With such data, researchers may better pinpoint pathway changes
 associated with diseases and more accurately select points of intervention for
 treatment," said John D. Rodwell, Ph.D, President and Chief Technology Officer
 of AxCell.  "We believe that these seminars have helped prepare the market for
 launch of ProChart this month."
     In addition, AxCell has finalized plans for expansion at its Newtown, PA
 facilities.  Construction will begin shortly which, when complete, will add
 approximately 5500 sq. ft. of workspace, virtually all of which will be used
 for laboratory space for increased molecular biology, chemistry and screening
 activities designed to accelerate the acquisition of protein interaction data
 for use in its ProChart database product and for more effective mining of its
 data.
     As part of its efforts to acquaint the pharmaceutical and biotechnology
 markets with its ProChart product, AxCell will be presenting at a number of
 future conferences.  The Company is currently scheduled to speak at the 5th
 Annual Congress on Drug Discovery in Stuttgart, Germany in April, the
 Proteomics 2001 Conference in Philadelphia in May, the HTT Expo in
 Philadelphia and the Proteomics Conference in San Francisco which both take
 place in June.
 
     Cytogen Hires Financial Advisor
     Cytogen Corporation is currently engaged in two highly competitive lines
 of business; oncology and proteomics.  Cytogen recognizes the need to
 strengthen each of its businesses in order to enhance shareholder value.
 Given the challenges of increasing shareholder value and raising capital in
 today's marketplace, the Board of directors has engaged UBS Warburg LLC as its
 financial advisor in order to assist the Company in pursuing various strategic
 alternatives, including but not limited to marketing arrangements, research
 and development collaborations, international collaborations, joint ventures
 and financing opportunities.
 
     About AxCell Biosciences
     AxCell Biosciences Corporation is conducting research and development in
 functional proteomics, the identification of protein interactions and
 signaling pathways within cells and their relationship to disease processes.
 Proteomics research efforts can be categorized as structural and functional.
 Structural proteomics, or protein expression, measures the number and types of
 proteins present in normal and diseased cells.  This approach is useful in
 defining the structure of proteins in a cell.  Some of these proteins may be
 targets for drug discovery.  However, the role of the protein in the disease
 is still not defined.  AxCell's proteomics business is focused upon functional
 proteomics, the study of proteins' biological activities.  An important
 function of proteins is the transmission of signals using intricate pathways
 populated by proteins which interact with one another.  Elucidating the role
 proteins play in these signaling pathways allows a better understanding of
 their function in cellular behavior and permits identification of potential
 drug targets.  Protein-protein interactions form the core of the Company's
 ProChart(TM) Database.  AxCell's plans to offer ProChart(TM) to the
 pharmaceutical industry as a tool to accelerate the drug discovery process.
 For additional information on AxCell Biosciences, visit www.axcellbio.com.
 
     About Cytogen Corporation
     Cytogen Corporation is a biopharmaceutical company based in Princeton, NJ.
 The Company's two principal lines of business, proteomics and oncology, are
 built upon its expertise in antibodies and molecular recognition and are
 directed principally to development of novel products for the diagnosis,
 imaging, staging and treatment of prostate cancer and a proteomics-driven drug
 discovery platform.  For additional information, visit www.cytogen.com.
 
     This press release contains certain "forward-looking" statements within
 the meaning of the Private Securities Litigation Reform Act of 1995.
 Information in this press release, which is not historical, is forward-looking
 and involves a number of risks and uncertainties including those discussed in
 the Company's 2000 Form 10-K and from time-to-time the Company's other filings
 with the Securities and Exchange Commission.  Investors are cautioned not to
 put any undue reliance on any forward-looking statement.  The Company's actual
 results may differ materially from those anticipated in these forward-looking
 statements.  Factors that may cause such differences include, but are not
 limited to, uncertainties associated with the Company's ability to sustain its
 intellectual property positions on its proteomics technology, and the
 successful development and market acceptance of the technology.  In
 particular, the Company cannot assure you that the protein interaction program
 will result in the commercialization of a successful product or whether any
 strategic alternative or financing will be available at all on terms that are
 in the best interests of the Company and its shareholders.  The Company
 specifically disclaims any intention or duty to update any forward-looking
 statements, and these statements represent the Company's outlook at this time.
 
 SOURCE  Cytogen Corporation

RELATED LINKS

http://www.cytogen.com